You are here

  • Home
  • Archive
  • Volume 4, Issue Suppl 1
  • 90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study

Article info

Article menu

Download PDFPDF

Poster Session
New therapies and therapeutic targets – SLE
90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study
Free

Authors

Citation

Chamberlain C, Colman P, Ranger A, et al
90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study
Lupus Science & Medicine 2017;4:doi: 10.1136/lupus-2017-000215.90

Publication history

  • First published March 24, 2017.
Online issue publication 
March 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions